- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04534985
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
April 7, 2023 updated by: University of Colorado, Denver
Time Restricted Feeding in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
The proposed research will determine the feasibility of a time restricted feeding intervention,a fasting regimen that restricts eating to a feeding window (8 hrs/day) for 1 year in adults with autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese.
The study will provide valuable information on the intervention in terms of safety, adherence, acceptability, and tolerability.
Last, this pilot trial will provide initial insight into biological changes including abdominal adiposity, changes in kidney growth and function, and markers of biological pathways related to the intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Mounting evidence suggests that a metabolic defect exists in autosomal dominant polycystic kidney disease (ADPKD), which likely contributes to cystic epithelial proliferation and subsequent cyst growth.
There are notable overlapping features and pathways among metabolism, obesity, and/or ADPKD.
The investigators recently reported that in the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Study A that overweight and obesity are strong independent predictors of more rapid kidney growth.
Moving beyond body mass index, the investigators have novel preliminary data using magnetic resonance images (MRIs) from a small number of participants from HALT-PKD Study A that abdominal adiposity is an independent predictor of kidney growth and kidney function decline.
Adipocytes do not simply act as a fat reservoir but are active endocrine organs that promote release of pro-inflammatory cytokines and produce adipokines.
Numerous signaling pathways promoted by adipocytes are also implicated in cystogenesis.
Periods of fasting may counter adiposity-mediated signaling pathways and slow ADPKD progression.
Mild-to-moderate food restriction profoundly slows cyst growth and maintains renal function in rodent models of ADPKD, which are characterized by metabolic reprogramming favoring enhanced aerobic glycolysis.
Notably, fasting promotes a shift from carbohydrate to fat metabolism, which could suppress cyst growth.
The investigators are currently conducting an ongoing behavioral weight loss pilot trial (based on either daily caloric restriction or intermittent fasting) in adults with ADPKD who are overweight/obese.
As an alternative to these approaches, time-restricted feeding (TRF) is a novel fasting regimen that restricts eating to a feeding window (typically 8-12 hrs/day).
As isocaloric TRF reduces disease progression in a rodent model of ADPKD, including kidney: body weight and mammalian target of rapamycin (mTOR) activity, it may be an alternative and easier to adhere to dietary strategy to slow ADPKD progression.
Specific Aim: Determine the feasibility of TRF without energy intake restriction in adults with ADPKD and overweight/obesity.
The study will determine adherence to TRF by assessing the percent of participants achieving the goal of eating within an 8-hour TRF window, measured objectively with a photographic food record and verified with continuous glucose monitoring data.
The study will also further assess the safety, acceptability, and tolerability of TRF by evaluation of safety labs, adverse events, and quality of life measures, as well as changes in abdominal adiposity and total kidney volume (TKV) by magnetic resonance imaging (MRI), and markers of biological pathways (AMP-activated protein kinase [AMPK], mTOR, insulin-like growth factor 1 [IGF1]).
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado - Anschutz Medical Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged 18-65 years
- ADPKD diagnosis based on the modified Pei-Ravine criteria
- BMI 25-45 kg/m^2
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimated glomerular filtration rate ≥30 mL/min/1.73 m^2
- Access to the internet with video chat capabilities and smartphone
- Typical eating duration >12 hrs/day
- Not currently participating in another interventional study or weight loss program
- Ability to provide informed consent
Exclusion Criteria:
- Diabetes mellitus (diagnosis or fasting glucose >126 mg/dL or Hemoglobin A1C >6.5%)
- Current nicotine use or history of use in the past 12 months
- Alcohol or substance abuse (self-report or undergoing treatment)
- History of hospitalization or major surgery within the last 3 months
- Untreated dyslipidemia (low density lipoprotein cholesterol > 190 mg/dL or triglycerides >400 mg/dL)
- Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)
- Pregnancy, lactation, or unwillingness to use adequate birth control
- Cardiovascular disease, peripheral vascular disease, cerebrovascular disease, significant pulmonary or gastrointestinal disease (described below), cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis)
- Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease
- Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants; study physician will be consulted as needed; antibiotics started during the intervention period are not an exclusion); regular use of obesity pharmacotherapeutic agents within the last 6 month
- History of clinically diagnosed eating disorder including anorexia nervosa, bulimia, binge eating disorder. Score >20 on the Eating Attitudes Test (EATS)-2653 will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
- Weight loss >5% in past 3 months for any reason except post-partum weight loss; weight gain >5% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
- Untreated hyper- or hyperthyroidism (TSH outside of normal range for laboratory or history of uncontrolled thyroid disorder). History of thyroid disorder or current thyroid disease treated with stable medication regimen for at least 6 months in acceptable.
- Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Score > 18 on the Beck Depression Inventory will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
- History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions.
- Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Time Restricted Feeding
Instructed to eat within an 8-hr window, beginning within 3 hrs of waking.
In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0
g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
|
Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
|
Active Comparator: Healthy Eating Advice without Time Restricted Feeding
Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0
g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
|
Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence
Time Frame: 1 year
|
Percent adherence to the 8-hr TRF window (during the 7 day recordng period)
|
1 year
|
Feasibility to enroll participants
Time Frame: Through study enrollment, an expected duration of 12 months
|
Numbers of individuals pre-screened and enrolled
|
Through study enrollment, an expected duration of 12 months
|
Feasibility to retain participants
Time Frame: Through study completion, an expected duration of 24 months
|
Numbers of individuals retained
|
Through study completion, an expected duration of 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability, measured as adverse events
Time Frame: Through study completion, an expected duration of 24 months
|
Number of participants with treatment-related adverse events in each group as evaluated by the Safety Officer
|
Through study completion, an expected duration of 24 months
|
Change in Body Weight
Time Frame: 1 year
|
Body weight will be measured at baseline and monthly, using BodyTrace scales for remote, secure transmission of data.
|
1 year
|
Change in Abdominal adiposity
Time Frame: 1 year
|
Abdominal adiposity will be quantified using MRI
|
1 year
|
Change in Body Composition
Time Frame: 1 year
|
Body composition measured via dual-energy X-ray absorptiometry (DEXA)
|
1 year
|
Change in insulin-like growth factor binding protein-1 levels
Time Frame: 1 year
|
Fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
|
1 year
|
Change in serum insulin-like growth factor-1 levels
Time Frame: 1 year
|
Fasting serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
|
1 year
|
Change in peripheral blood mononuclear cell (PBMC) AMPK expression
Time Frame: 1 year
|
Peripheral blood mononuclear cell protein expression of AMP-activated kinase (AMPK) in each group
|
1 year
|
Change in PBMC S6K expression
Time Frame: 1 year
|
Peripheral blood mononuclear cell protein expression of S6 kinase (S6K) in each group
|
1 year
|
Change in β-hydroxybutyrate levels
Time Frame: 1 year
|
Serum β-hydroxybutyrate levels in each group
|
1 year
|
Change in total kidney volume by magnetic resonance imaging (MRI)
Time Frame: 1 year
|
Change in total kidney volume by MRI in each group
|
1 year
|
Change in quality of life
Time Frame: 1 year
|
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score
|
1 year
|
Change in mood
Time Frame: 1 year
|
Mood state will be assessed with the Profile of Mood States 2 (POMS-2)
|
1 year
|
Change in pain
Time Frame: 1 year
|
Modified version of the Wisconsin Brief Pain Survey
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in resting energy expenditure
Time Frame: 1 year
|
Standard indirect calorimetry
|
1 year
|
Change in energy intake
Time Frame: 1 year
|
24-hr dietary recalls will be analyzed using a random day in the 7-day photographic food record/continuous glucose monitoring collection period to evaluate self-reported energy intake
|
1 year
|
Change in macronutrient intake
Time Frame: 1 year
|
24-hr dietary recalls will be analyzed using a random day in the 7-day photographic food record/CGM collection period to evaluate self-reported energy intake
|
1 year
|
Change in self-reported physical activity
Time Frame: 1 year
|
Self-reported physical activity will be quantified using the Stanford Physical Activity Questionnaire
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristen Nowak, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 9, 2021
Primary Completion (Actual)
March 31, 2023
Study Completion (Actual)
March 31, 2023
Study Registration Dates
First Submitted
August 25, 2020
First Submitted That Met QC Criteria
August 27, 2020
First Posted (Actual)
September 1, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2023
Last Update Submitted That Met QC Criteria
April 7, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Musculoskeletal Abnormalities
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Kidney Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Arthrogryposis
Other Study ID Numbers
- 20-1262
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data obtained through this study may be provided to qualified researchers with academic interest in ADPKD.
Data shared will be coded, with no PHI included.
Approval of the request and execution of all applicable agreements (i.e.
data use agreement) are prerequisites to the sharing of data with the requesting party.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months.
Extensions will be considered on a case-by-case basis.
IPD Sharing Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Kidney, Autosomal Dominant
-
Emory UniversityPKD FoundationCompleted
-
Mario Negri Institute for Pharmacological ResearchOtsuka Pharmaceutical Italy S.r.l.CompletedAutosomal Dominant Polycystic Kidney DiseaseItaly
-
Mayo ClinicUniversity of Kansas Medical CenterCompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
CHU de ReimsCompletedAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Regional Hospital HolstebroAarhus University HospitalCompletedAutosomal Dominant Polycystic Kidney DiseaseDenmark
-
University Hospital, BrestUnknownAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Federico II UniversityCompletedAutosomal Dominant Polycystic Kidney Disease
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Kyorin UniversityUnknown
Clinical Trials on Dietary
-
University Hospital, ToulouseCompleted
-
University of ViennaCompletedEndotoxemia | Dietary HabitsAustria
-
Center of Food and Fermentation TechnologiesCompleted
-
Heriot-Watt UniversityUniversity of EdinburghCompleted
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
University of AlbertaCargill; Canada Foundation for Innovation; Nestlé Health Science Spain; Government... and other collaboratorsCompleted
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Federal University of Rio Grande do SulNot yet recruitingEffects of Time-restricted Eating and Aerobic Exercise Training in Women With Overweight and ObesityObesity | Overweight and Obesity | Time Restricted Feeding | Intermittent Fasting | Time Restricted Eating
-
Vanderbilt UniversityWithdrawn
-
University of Novi Sad, Faculty of Sport and Physical...Completed